21. COMMITMENTS AND CONTINGENCIES Lease Commitments In the U.S., the Company leases office, warehousing and manufacturing facilities under several operating lease agreements expiring at various dates through fiscal 2017 with a right to renew for an additional term in the case of most of the leases. Certain of these leases contain escalation clauses. Outside the U.S., the Company leases foreign office and warehouse facilities under operating lease agreements expiring at various dates through fiscal 2019. The total leasing expense for the Company was $3.1 million in the Successor fiscal 2012 period, $0.9 million in the Predecessor fiscal 2012 period, $4.3 million in fiscal 2011 and $3.8 million in fiscal 2010. The following is a schedule of approximate future annual lease payments under all operating leases that have initial or remaining non-cancelable lease terms as of May 31, 2012 (in thousands): Year Ending May 31: 2013 $ 3,870 2014 3,174 2015 2,803 2016 2,459 2017 916 Thereafter 1,281 $ 14,503 Purchase Commitments Purchase commitments made in the normal course of business were $23.3 million as of May 31, 2012. Contingencies In October 2007, the Company reported that the Federal Trade Commission ( FTC ) was investigating whether Immucor violated federal antitrust laws or engaged in unfair methods of competition through three acquisitions made in the period from 1996 through 1999, and whether Immucor or others engaged in unfair methods of competition by restricting price competition. The Company has provided certain documents and information to the FTC concerning those acquisitions and concerning our product pricing activities since then. The Company has cooperated with the FTC throughout this process. As was previously the case, at this time the Company cannot reasonably assess the timing or outcome of the investigation or its effect, if any, on its business. Beginning in May 2009, a series of class action lawsuits was filed against the Company, Ortho-Clinical Diagnostics, Inc. and Johnson &amp; Johnson Health C